SCHEMBL4122863

SCHEMBL4122863

COc1cccc(CO)c1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDCD1 Q15116 2/20 0.51
CD274 Q9NZQ7 2/20 0.51
PDE4A P27815 1/20 0.45
PDE4B Q07343 1/20 0.45
PDE4C Q08493 1/20 0.45
PDE4D Q08499 1/20 0.45
IDO1 P14902 3/20 0.44
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
MAPT P10636 2/20 0.43
HPGD P15428 2/20 0.43
LMNA P02545 2/20 0.43
TP53 P04637 1/20 0.43
CYP3A4 P08684 1/20 0.43
ALOX15 P16050 1/20 0.43
ALOX12 P18054 1/20 0.43
MAPK1 P28482 1/20 0.43
HSD17B10 Q99714 1/20 0.43
ALOX5 P09917 1/20 0.43
PTGS2 P35354 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15296216 0.84 ALOX5 (0.45) PDCD1CD274IDO1KDM4EALDH1A1
SCHEMBL31689793 0.83 TAAR1 (0.50) IDO1ALDH1A1MAPTALOX5PTGS2
SCHEMBL31689794 0.83 TAAR1 (0.50) IDO1ALDH1A1MAPTALOX5PTGS2
SCHEMBL6172042 0.81 ALOX5 (0.50) PDCD1CD274IDO1KDM4EALDH1A1
SCHEMBL3903483 0.81 PDCD1 (0.44) PDCD1CD274MAPTLMNAMAPK1
SCHEMBL12948348 0.81 L3MBTL1 (0.47) IDO1KDM4EMAPTHPGDLMNA
SCHEMBL4598965 0.81 MEN1 (0.51) PDCD1CD274PDE4APDE4BPDE4C
SCHEMBL30829273 0.80 IDO1 (0.57) PDE4APDE4BPDE4CPDE4DIDO1
SCHEMBL17820 0.80 IDO1 (0.57) PDE4APDE4BPDE4CPDE4DIDO1
SCHEMBL2354192 0.80 PDCD1 (0.47) PDCD1CD274KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025080653-A1 PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUNDS ACTING AGAINST CANCERS, INFLAMMATORY DISEASES, AND FIBROTIC DISEASE VIA INTERACTION WITH RAS SUPERFAMILY PROTEINS SHY THERAPEUTICS, LLC (US) 2025-04-17 WO disclosed
US-20250115577-A1 BCL-2 Inhibitors Eil Therapeutics, Inc. 2025-04-10 US disclosed
EP-4457223-A1 BCL-2 INHIBITORS Eil Therapeutics, Inc. (US) 2024-11-06 EP disclosed
CN-118451070-A BCL-2 inhibitors 伊尔治疗学股份有限公司 2024-08-06 CN disclosed
WO-2023129553-A1 BCL-2 INHIBITORS Eil Therapeutics, Inc. (US) 2023-07-06 WO disclosed
WO-2023129553-A1 BCL-2 INHIBITORS Eil Therapeutics, Inc. (US) 2023-07-06 WO disclosed
EP-3541792-B1 TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR AMGEN INC (US) 2020-12-23 EP disclosed
EP-3172202-B1 HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE BOEHRINGER INGELHEIM INT (DE) 2020-01-29 EP disclosed
EP-2892891-B1 ALKOXY PYRAZOLES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS BOEHRINGER INGELHEIM INT (DE) 2019-07-31 EP disclosed
US-20180162864-A1 PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF AND COMPOSITIONS CONTAINING THE PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 2018-06-14 US disclosed
US-20070203116-A1 Dihydrospiro[dibenzo[a,d][7]annulene-5,4'-imidazol] compounds for the inhibition of beta-secretase WYETH (US) 2007-08-30 US disclosed
US-20070203116-A1 Dihydrospiro[dibenzo[a,d][7]annulene-5,4'-imidazol] compounds for the inhibition of beta-secretase WYETH (US) 2007-08-30 US disclosed
WO-2006010965-A1 INDOLE-2 -CARBOXAMIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS Richter Gedeon Vegyészeti Gyár Rt. (HU) 2006-02-02 WO disclosed
EP-0966446-B1 BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE WARNER LAMBERT CO (US) 2005-10-19 EP disclosed
US-6528535-B2 Anticancer agents; restenosis WARNER-LAMBERT COMPANY 2003-03-04 US disclosed
US-20020006936-A1 Bicyclic inhibitors of protein farnesyl transferase BIKKER JACK (US) 2002-01-17 US disclosed
US-6265422-B1 ANTICANCER AGENTS; CARDIOVASCULAR DISORDERS WARNER-LAMBERT COMPANY 2001-07-24 US disclosed
US-6133303-A VARIOUS INDENE DERIVATIVES, WITH THE EXCEPTION OF 5-(2-IMIDAZOLE-1-YL-ETHOXY)INDAN-1-ONE; TREATING CANCER AND TREATING OR PREVENTING RESTENOSIS OR ATHEROSCLEROSIS WARNER-LAMBERT COMPANY (US) 2000-10-17 US disclosed
EP-0966446-A1 BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE WARNER-LAMBERT COMPANY (US) 1999-12-29 EP disclosed
WO-1998034921-A1 BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE WARNER-LAMBERT COMPANY (US) 1998-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250115577-A1 BCL-2 Inhibitors BCL2, BCL2L1, BCL2L2 PDCD1 470/4885CD274 2974/4885PDE4A 3337/4885
US-20070203116-A1 Dihydrospiro[dibenzo[a,d][7]annulene-5,4'-imidazol] compounds for the inhibition of beta-secretase BACE1, BACE2, APP PDCD1 844/4885CD274 2926/4885PDE4A 2585/4885
US-20180162864-A1 PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF AND COMPOSITIONS CONTAINING THE PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF KRAS, DPYD, PSTPIP2 PDCD1 109/4885CD274 1139/4885PDE4A 1665/4885
US-20020006936-A1 Bicyclic inhibitors of protein farnesyl transferase FNTA, FNTB, SREBF1 PDCD1 4594/4885CD274 4787/4885PDE4A 2156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.